During January 2020, persons in Thailand were tested for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection if they had a combination of fever or respiratory illness and a history of travel to Wuhan, China. Persons determined to be close contacts of a laboratory-confirmed coronavirus disease (COVID-19) case-patient also were tested during enrollment into contact tracing. Clinicians were able to request testing if they had a concern regarding persons who were exposed to travelers. During January 8--31, 2020, Bamrasnaradura Infectious Diseases Institute, the national infectious disease referral hospital in Bangkok, admitted 11 patients with laboratory-confirmed COVID-19. We describe clinical features, clinical management, and results of serial reverse transcription PCR (RT-PCR) testing for SARS-CoV-2 RNA for these patients.

The Study
=========

The 11 hospitalized patients had daily nasopharyngeal and oropharyngeal sampling for SARS-CoV-2 RNA testing. Specimens were collected by using synthetic fiber swabs, which were combined and placed into a single sterile tube containing ≈3 mL of viral transport medium. RNA was extracted and tested with conventional RT-PCR and real-time RT-PCR (rRT-PCR). We developed SARS-CoV-2--specific primers and probes by using a protocol from the World Health Organization ([@R1]) and validated results by using clinical specimens. Nasopharyngeal and oropharyngeal swabs and sputum specimens also were tested for 33 respiratory pathogens by using the Fast-Track Diagnostic rRT-PCR Respiratory Panel (Fast Track Diagnostics, <http://www.fast-trackdiagnostics.com>), according to the manufacturer's instructions. During the study period, Thailand's discharge criteria for hospitalized COVID-19 patients required resolution of clinical signs and symptoms and 2 respiratory specimens without detectable SARS-CoV-2 RNA collected [\>]{.ul}24 hours apart.

The median age of the patients was 61 years (range 28--74 years; [Table 1](#T1){ref-type="table"}). Cough, malaise, and sore throat were the most common signs and symptoms among the 11 patients ([Figure 1](#F1){ref-type="fig"}). In patients with fever (temperature \>38°C; 10/11), defervescence took a median of 6 days (4--11.5 days). Some patients had signs and symptoms that lasted [\>]{.ul}10 days ([Figure 1](#F1){ref-type="fig"}; [Table 2](#T2){ref-type="table"}). Most patients received supportive care; none required mechanical or noninvasive ventilation during their hospitalization.

###### Demographics, baseline characteristics, illness histories, laboratory values and treatment therapies of confirmed COVID-19 patients in Bamrasnaradura Infectious Diseases Institute, Bangkok, Thailand, 2020\*

  Demographics                                               Patient no.   Total, %                                                                                                               
  ---------------------------------------------------------- ------------- ---------- ------- ------ ------ ------ ------- ------- ------------ ------------- --------- ------------------------- --
  Age, y/sex                                                 61/F          74/F       68/M    66/F   57/F   34/M   61/M    63/M    28/F         51/M          49/M      55 M/45 F                 
  Ethnicity                                                  CH            CH         CH      CH     CH     CH     CH      CH      CH           TH            TH        82 CH/18 TH               
  Occupation                                                 Ret           Ret        Ret     Ret    Ret    EE     Ret     Ret     Tour guide   Taxi driver   Officer   54 Ret/46 other           
  Detected through airport screening                         Y             Y          Y       N      N      N      N       N       N            N             N         27 Y/73 N                 
  Detected through contact tracing                           N             N          N       Y      N      N      N       N       N            N             N         9 Y/91 N                  
  Detected after patient voluntarily sought medical care     N             N          N       N      Y      Y      Y       Y       Y            Y             Y         64 Y/36 N                 
  Visited Hunan Seafood Market                               N             N          N       N      N      N      N       N       N            N             N         0                         
  Underlying conditions                                                                                                                                                                           
  Diabetes                                                   N             N          N       N      N      Y      N       N       N            Y             N         18 Y/82 N                 
  Hypertension                                               Y             Y          N       Y      N      N      N       N       N            Y             N         36 Y/64 N                 
  COPD                                                       N             N          N       N      N      N      N       N       N            N             N         0                         
  Asthma                                                     N             N          N       N      N      N      N       N       N            N             N         0                         
  Cancer                                                     N             N          N       N      N      N      N       N       N            N             N         0                         
  Cardiovascular disease                                     N             Y          N       Y      N      N      N       Y       N            N             N         27 Y/73 N                 
  Cerebrovascular disease                                    N             N          N       N      N      N      N       Y       N            N             N         9 Y/91 N                  
  Chronic liver disease                                      N             N          N       N      N      N      N       N       N            N             Y         9 Y/91 N                  
  Any chronic condition                                      Y             Y          N       Y      N      Y      N       Y       N            Y             Y         64 Y/36 N                 
  Current smoker                                             N             N          N       N      N      N      N       N       N            N             N         0                         
  Pregnant                                                   NA            NA         NA      NA     NA     NA     NA      NA      N            NA            NA        0                         
  Laboratory values at time of admission (reference range)                                                                                                                                        
  Leukocytes ×10^9^/L (4.5--8)                               1.9↓          3.3↓       4       3.6    3.9    3.4↓   5.8     4.1     4.9          5.8           2.5↓                                
  Neutrophils, % (36--70)                                    48            64         66      63     56     80↑    63      83      73↑          58            54                                  
  Lymphocytes, % (23--57)                                    40            19↓        25      25     33     1↓     30      16↓     23           31            30                                  
  Platelets ×10^6^ /μL (140--400)                            127↓          16.4↓      12.6↓   177    167    169    168     18.4↓   153          368           167                                 
  Hemoglobin, g/dL (11--14)                                  13.3          12.8       11.5    13.1   13.2   13.3   15.3↑   13.8    11.4         14            14.8↑                               
  Hematocrit, % (35--41)                                     38            38         33↓     37     37.9   38     45↑     39      34           41            43↑                                 
  ALT, U/L (0--31)                                           18            27         18      83↑    23     16     22      22      24           24            26                                  
  AST, U/L (0--31)                                           14            12         15      47↑    16     19     20      14      25           16            22                                  
  Other diagnostics                                                                                                                                                                               
  Oxygen saturation on room air at admission                 98            97         95      98     99     99     98      99      96           91↓           97                                  
  Results from Biofire-33 multiplex PCR‡                                                                                                                                                          
  *Haemophilus influenzae*                                   \+            \+         --      --     \+     \+     --      --      --           --            --                                  
  Adenovirus                                                 --            *+*        --      --     --     --     --      --      --           --            --                                  
  Influenza A                                                --            --         --      --     --     --     \+      --      --           --            --                                  
  *Klebsiella pneumoniae*                                    --            --         --      --     --     --     --      --      --           --            \+                                  
  Treatments                                                                                                                                                                                      
  Antimicrobial drugs, dose                                                                                                                                                                       
  Ceftriaxone, 2 g 4×/d IV                                   1             0          7       0      0      0      7       0       0            7             0                                   
  Ceftriaxone, 2 g/d orally                                  0             7          0       0      0      0      0       0       0            0             0                                   
  AMOX/CLAV, 2 g 4×/d orally                                 6             0          0       0      0      0      0       0       0            0             7                                   
  Oseltamivir, 150 mg 4×/d orally                            5             0          0       0      0      0      5       0       0            0             5                                   
  Nasal cannula, 5 L, no. days                               0             0          0       0      0      0      0       0       0            3             0                                   
  Duration of signs and symptoms reported at admission, d                                                                                                               Median (IQR)/ mean (SD)   
  Cough                                                      1             1          1       0      2      1      4       2       3            8             5         2 (1--4)/2.5 (2.3)        
  Malaise or fatigue                                         4             2          4       0      2      4      13      2       3            5             5         4 (2--5)/4.0 (3.3)        
  Fever                                                      2             2          4       0      3      4      4       2       2            8             5         3 (2--4)/3.3 (2.1)        
  Sore throat                                                4             0          3       0      3      2      4       2       3            7             5         3 (2--4)/3.0 (2.0)        
  Rhinorrhea                                                 2             2          4       0      2      1      3       2       2            2             4         2 (2--3)/2.2 (1.2)        
  Headache                                                   1             0          2       0      0      0      0       2       1            5             3         1 (0--2)/1.3 (1.6)        
  Vomiting                                                   0             1          1       0      0      0      0       1       0            0             0         0 (0--1)/0.3 (0.5)        
  Diarrhea                                                   0             0          1       0      0      0      0       1       0            0             0         0/0.2 (0.4)               

\*ALT, alanine aminotransferase; AMOX/CLAV, amoxicillin/clavulanate; AST, aspartate aminotransferase; COVID-19, coronavirus disease; CH, Chinese; EE, electrical engineer; IV, intravenous; NA, not applicable; Ret, retired; TH, Thai; ↓, low; ↑, high; +, positive; --, negative.  †([@R2])  ‡BioFire Diagnostics (<https://www.biofiredx.com>)
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###### Clinical illness history and calculated intervals of confirmed COVID-19 patients in Bamrasnaradura Infectious Diseases Institute, Bangkok, Thailand, 2020\*

  Duration of signs and symptoms, d      Median no. days since symptom onset (IQR)   Mean no. days since symptom onset (SD)   T-test comparison between means                  
  ----------------------------------- -- ------------------------------------------- ---------------------------------------- --------------------------------- -- -- -- -- -- --
                                                                                                                                                                               

  Patient no.                                                                                                                                      
  ------------------------------------------------------------ ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- --------------- ------------ ------
  Onset of symptoms                                            0    0    0    NA   0    0    0    0    0    0    0    NA              NA           NA
  Onset of fever                                               2    0    0    NA   0    0    9    0    1    0    0    0 (0--1.25)     1.2 (2.8)    --
  First medical visit                                          4    2    4    0    3    4    13   2    3    3    2    3 (2--4)        3.6 (3.3)    --
  Admitted to BIDI                                             4    2    4    0    3    4    13   2    3    8    5    4 (2--5)        4.4 (3.5)    --
  SARS-CoV-2 RNA detected                                      4    2    4    0    3    4    13   2    3    8    5    4 (2--5)        4.4 (3.5)    --
  Fever resolution                                             4    3    6    NA   6    4    13   4    6    13   11   6 (4--11.5)     7.0 (3.9)    --
  Clinical resolution                                          13   10   11   NA   9    9    17   15   9    13   13   12 (9--13.5)    11.9 (2.8)   --
  SARS-CoV-2 RNA undetectable                                  14   10   13   4    9    26   24   29   9    14   30   14 (9--26)      16.5 (9.1)   --
  Discharge                                                    15   11   14   6    15   29   26   32   11   16   33   15 (11--29)     18.9 (9.4)   --
  Calculated intervals                                                                                                                             
  Admission to discharge                                       11   9    10   6    12   25   13   30   8    8    28   11 (8--25)      14.5 (8.7)   --
  Fever resolution to SARS-COV-2 RNA undetectable              10   7    7    NA   3    22   11   25   3    1    19   9 (3--19.75)    10.8 (8.4)   --
  Admission to fever resolution                                0    1    2    NA   3    0    0    2    3    5    6    2 (0--3.5)      2.2 (2.1)    --
  Fever resolution to clinical resolution                      9    7    5    NA   3    5    4    11   3    0    2    5 (3--7.5)      4.9 (3.3)    --
  Admission to clinical resolution                             9    8    7    NA   6    5    4    13   6    5    8    7 (5--8.25)     7.1 (2.6)    --
  Fever onset to fever resolution                              2    3    6    NA   6    4    4    4    5    13   11   5 (4--7.25)     5.8 (3.5)    --
  Admission to SARS-COV-2 RNA undetectable                     10   8    9    4    6    22   11   27   6    6    25   10 (6--22.75)   12.2 (8.3)   --
  Fever resolution to discharge                                11   8    8    NA   9    25   13   28   5    3    22   10 (7--22.75)   13.2 (8.7)   --
  Fever duration by stratified condition                                                                                                           
  Patients detected through airport screening                  2    3    6    --   --   --   --   --   --   --   --   3 (2--6)        3.7 (2.1)    0.14
  Patients seeking medical care                                --   --   --   --   6    4    4    4    5    13   11   5 (4--11)       6.7 (3.7)    --
  Detectable SARS-COV-2 RNA duration by stratified condition                                                                                       
  Patients detected through airport screening                  10   9    8    --   --   --   --   --   --   --   --   9 (8--10)       9.0 (1.0)    0.17
  Patients seeking medical care                                --   --   --   --   6    22   11   27   6    6    25   11 (6--25)      14.7 (9.6)   --

\*COVID-19, coronavirus disease; NA, not applicable †Patient 4 was asymptomatic throughout hospitalization and PCR results reflects days with detectable SARS-CoV-2 RNA following admission.

Patient 4 remained asymptomatic throughout hospitalization despite daily monitoring. However, her chest radiograph at admission revealed unilateral pneumonia ([Appendix](#SD1){ref-type="local-data"} Figure). Patient 4's nasopharyngeal and oropharyngeal specimens had detectable SARS-CoV-2 RNA on 4 consecutive days. She finally had 2 negative specimens separated by [\>]{.ul}24 hours and was discharged on day 7 after symptom onset ([Figure 2](#F2){ref-type="fig"}).
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Patient 10, a taxi driver with no history of air travel, had the most severe clinical presentation among these cases ([@R2]). He reported close contact while transporting symptomatic travelers from China, a mechanism of exposure that has been described elsewhere ([@R3]--[@R5]). Patient 10 did not seek care for 10 days after his reported onset of fever. In Thailand, workers in the tourist industry, including those who transport tourists, are among the risk groups monitored for occupational exposures under updated clinical practice guidelines ([@R6]).

We detected viral co-infections in 2 patients during their hospitalization. Patient 2 had an adenovirus co-infection, and patient 7 had an influenza A virus co-infection ([Table 1](#T1){ref-type="table"}). Patient 7 was hospitalized for 13 days and influenza might have contributed to his clinical course. In Thailand, influenza A infection occurs most frequently during the rainy season, July--November ([@R7]).

Conclusions
===========

We describe the clinical characteristics, clinical management, and laboratory findings from 11 COVID-19 patients hospitalized at Bamrasnaradura Infectious Diseases Institute. Most were febrile, but the onset of fever occurred early in the course of illness and fever resolution occurred 5 days before full clinical recovery and 10 days before discharge. Although no patient required mechanical ventilation or intubation, all had radiographic evidence of pneumonia, even those without respiratory symptoms. Together, these findings suggest that whereas fever and lower respiratory illness are commonly observed, case definitions requiring both fever and lower respiratory illness as signs and symptoms might not have detected several of these cases, especially later in the clinical course of illness.

Clinical resolution occurred a median of 12 (9--13.5) days after illness onset, and these patients had detectable SARS-CoV-2 RNA in upper respiratory tract specimens for a median of 14 (9--26) days after illness onset ([Table 2](#T2){ref-type="table"}). However, patients became afebrile 6 days after illness onset, with a median of 9 (3--19.75) additional days of detectable SARS-CoV-2 RNA in respiratory specimens after resolution of fever ([Table 2](#T2){ref-type="table"}). The required duration of hospitalization and observed period of viral RNA positivity for these patients underscore the potential burden of COVID-19 patients on hospital, diagnostic, treatment, and isolation capacities. Despite mild-to-moderate illness, the protracted period of SARS-CoV-2 RNA positivity in these patients' specimens might indicate a lengthy period of infectiousness and highlights risks to providers caring for COVID-19 patients.

Among persons of Chinese ethnicity in our study, only 3/9 who traveled from China were detected through airport screening. During the study period, \<7% of all persons under investigation for COVID-19 in Thailand were detected through airport screening ([@R8]). Given the proportion of cases identified through community surveillance, countries should not focus exclusively on point of entry screening or travel histories to detect cases of COVID-19, and maintaining healthcare providers' awareness remains critical.

Patient 4 had detectable SARS-CoV-2 RNA for 4 consecutive days, but we were only able to follow her for 7 days before she returned to China. Her case is an example of a person without reported symptoms but radiologic evidence of disease and detectable virus over several days. Other studies have described asymptomatic patients with upper respiratory specimens positive for SARS-CoV-2 ([@R9]), and evidence suggests such cases pose a risk for transmission ([@R10]*--*[@R12]).

Our case series has some limitations. Patients could have recall bias regarding symptom onset before hospitalization. We were unable to complete a 14-day observation for some patients because they returned to China after discharge, including patient 4, who had no reported respiratory symptoms.

The relatively long duration of hospitalizations in our study highlights the effects that current surveillance and isolation procedures can have on clinical care surge capacity. Duration of hospitalization was extended by Ministry of Public Health requirements for patients to remain in the hospital until symptom resolution and clearing of SARS-CoV-2 RNA in clinical samples. We observed that it took a median of 9 days to clear SARS-CoV-2 after fever resolution. In addition, we noted serial detection of SARS-CoV-2 RNA in respiratory specimens of an asymptomatic patient.

Our observations of possible viral co-infections in COVID-19 patients and the resolution of fever relatively early during clinical course also have implications for surveillance strategies. Specifically, case definitions requiring fever could miss COVID-19 cases, especially later in the clinical course, and surveillance strategies that test only for SARS-CoV-2 could miss co-infections. Clinicians should consider the possibility of co-infection because the presence of other respiratory pathogens does not exclude the possibility of SARS-CoV-2 virus infection. Clinicians also need to better understand the relationship of RT-PCR detection of SARS-Cov-2 via multiple shedding routes ([@R13]) compared with the presence of culturable virus, especially in patients with few or no symptoms, because this might affect screening and isolation criteria. Whereas the current outbreak will undoubtedly change in character and magnitude, the information in this report could be combined with additional data sources to refine public health response and clinical management.

###### Appendix

Additional information on hospitalized patients diagnosed with coronavirus disease, Thailand.
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